ILS Course

In association with the Resuscitation Council UK, Richmond Pharmacology’s highly trained Resuscitation and Clinical Skills Practitioners now provide Immediate Life Support training.

ILS Course Registration Form

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Due to the COVID-19 pandemic, we have unfortunately had to cancel all our planned dates for the remainder of 2020. We hope to be in a position to restart ILS courses at the beginning of 2021 therefore please keep an eye on our website for further updates.

These courses will equip external healthcare professionals with the skills to assist patients in preventing or treating cardiac arrest. Richmond Pharmacology will offer an E-ILS (£80) and Full ILS Course (£120).

Registration Form

Full ILS Course 2020


6. Friday 27th March 2020 09:00-16:00
7. Friday 3rd April 2020 09:00-16:00
8. Tuesday 28th April 2020 09:00-16:00
9. Thursday 14th May 2020 09:00-16:00
10. Wednesday 27th May 2020 09:00-16:00

11. Friday 12th June 2020 09:00-16:00
12. Tuesday 23rd June 2020 09:00-16:00

To find out more information on the ILS Training, please email us: courses@richmondpharmacology.com

Additionally, to find out more about the ILS training courses offered by the Resuscitation Council (UK), please check here.

Courses will be held:

St John Ambulance London Bridge
Lyon House
160-166 Borough High Street
London
SE1 1LB

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more